Sequencing
News on NGS technologies, RNA-seq, clinical sequencing, & sample prep in genetics, genomics, and molecular diagnostics.
Foresight Diagnostics Founders Respond to Roche Lawsuit, Says Claims Asserted in Bad Faith
Foresight said that Roche's asserted trade secrets were not secret and that the technologies at the heart of the claim are fundamentally different.
The firm last week announced it received funding that will allow it to complete development of the test, called Myelo-Scan, by the end of 2026.
The firm has submitted its xR assay to the FDA and is prioritizing its entry into the minimal residual disease space.
Foundation Medicine Nabs Five-Year VA Contract for Tumor Molecular Profiling of Cancer Patients
The national contract covers FoundationOne CDx, FoundationOne Liquid CDx, FoundationOne RNA, and FoundationOne Heme.
Angle Acquires Option to License NuProbe Pan-Cancer NGS Panel
Angle said the panel would help advance its efforts to develop a liquid biopsy assay for circulating tumor cells and ctDNA.